Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-11-07. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellpurposesubjectventriculartransplant
  Phrases that lowered it: participantparticipantslymphoma20rituximab
• Sponsor's past termination rate: 4.4% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 110 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor's past trials: 410 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 25.4% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 97466 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports marked serious: 89.4% (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma NCT00633594 · started 2008 · scored riskier than 75% of active trials completed
• Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma NCT01035463 · started 2009 · scored riskier than 95% of active trials completed
• R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL NCT01865110 · started 2013 · scored riskier than 90% of active trials completed
• A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The EMERGE Trial NCT00737529 · started 2008 · scored riskier than 64% of active trials completed
• Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma NCT01472562 · started 2011 · scored riskier than 90% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.